Revolution Medicines’ pan-RAS inhibitor helped patients with a highly aggressive form of pancreatic cancer live an average of six months longer than chemotherapy, hitting a goal of the phase 3 study.

After dropping headline-grabbing phase 3 data for its pancreatic cancer candidate daraxonrasib last week, Revolution Medicines is not resting on its laurels. The Bay Area biotech has spent several ...

SINGAPORE – Illegal modifications and unauthorised repairs remain longstanding safety concerns for electric vehicles (EVs). And though these modifications pose risks to internal combustion engine (ICE ...

For hockey fans, it’s the best time of the year. The Stanley Cup Playoffs are officially here, and after a regular season defined by historic turnarounds and shifting divisional powers, the 2026 ...

What started the DISH–Gray Media blackout? The disruption began on March 10, 2026, when retransmission consent negotiations between DISH and Gray Media failed just ahead of a contract renewal deadline ...

A Revolution Medicines drug helped pancreatic cancer patients live nearly six months longer compared to those treated with standard of care chemotherapy, meeting the goals of a pivotal study in this ...

The 2025-26 NBA regular season has reached its conclusion, setting the stage for a postseason defined by high-stakes matchups and a brand-new broadcast landscape. The journey to the Larry O'Brien ...

MIAMI, Fla. — On Tuesday, Florida Gov. Ron DeSantis announced he planned to sign two bills, CS 56, Geoengineering and Weather Modification Activities, and CS 700 Department of Agriculture and Consumer ...

The biggest stories of the day delivered to your inbox.

Matt Elliott is a senior editor at CNET with a focus on laptops and streaming services. Matt has more than 20 years of experience testing and reviewing laptops. He has worked for CNET in New York and ...